This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
Full approval will depend on verification of clinical benefit in a confirmatory trial
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
NUFYMCO BLA has been approved by the USFDA
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
Subscribe To Our Newsletter & Stay Updated
